phentermine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anorexics 2140 122-09-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • phentermine
  • duromine
  • normephentermine
  • phentermine hydrochloride
  • phentermine HCl
  • phentermine resin complex
A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
  • Molecular weight: 149.24
  • Formula: C10H15N
  • CLOGP: 2.14
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -2.29
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.19 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
S (Water solubility) 2 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 4, 1959 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholecystitis chronic 172.57 17.09 58 6772 10303 63471889
Gallbladder disorder 75.50 17.09 38 6792 18804 63463388
Emotional distress 73.53 17.09 45 6785 32504 63449688
Injury 71.93 17.09 61 6769 73186 63409006
Arteriospasm coronary 65.19 17.09 22 6808 3946 63478246
Carotid artery dissection 64.92 17.09 12 6818 172 63482020
Anxiety 64.72 17.09 97 6733 217444 63264748
Drug abuse 62.35 17.09 56 6774 72462 63409730
Phospholipidosis 52.78 17.09 10 6820 165 63482027
Psoriasis 50.17 17.09 54 6776 86903 63395289
Cholelithiasis 48.13 17.09 39 6791 43886 63438306
Subarachnoid haemorrhage 43.54 17.09 24 6806 14259 63467933
Completed suicide 37.72 17.09 61 6769 145612 63336580
Dermatitis atopic 34.28 17.09 18 6812 9706 63472486
Deep vein thrombosis 33.28 17.09 43 6787 83757 63398435
Anhedonia 32.24 17.09 18 6812 10956 63471236
Encephalomalacia 32.19 17.09 8 6822 485 63481707
Spinal cord infarction 31.58 17.09 7 6823 257 63481935
Stress cardiomyopathy 29.13 17.09 16 6814 9434 63472758
Product dose omission issue 26.85 17.09 70 6760 234243 63247949
Device dislocation 26.42 17.09 22 6808 25683 63456509
Biliary dyskinesia 25.58 17.09 10 6820 2719 63479473
Colitis ischaemic 24.67 17.09 15 6815 10693 63471499
Renal vein thrombosis 23.64 17.09 6 6824 396 63481796
Drug intolerance 23.06 17.09 3 6827 308658 63173534
Depression 22.81 17.09 59 6771 196433 63285759
Pseudomembranous colitis 20.96 17.09 9 6821 3103 63479089
Subacute cutaneous lupus erythematosus 18.99 17.09 8 6822 2635 63479557
Pain 18.86 17.09 140 6690 740488 62741704
Medical device discomfort 17.81 17.09 7 6823 1932 63480260
Cholecystitis acute 17.57 17.09 11 6819 8249 63473943
Amyloidosis 17.49 17.09 6 6824 1129 63481063

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 59.19 27.03 36 955 99060 34856880

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholecystitis chronic 159.70 18.72 50 6140 9856 79728342
Drug abuse 95.93 18.72 88 6102 162603 79575595
Injury 77.40 18.72 57 6133 77439 79660759
Emotional distress 68.06 18.72 41 6149 39928 79698270
Arteriospasm coronary 64.66 18.72 23 6167 6693 79731505
Gallbladder disorder 61.41 18.72 30 6160 19310 79718888
Carotid artery dissection 60.89 18.72 12 6178 345 79737853
Completed suicide 56.97 18.72 82 6108 245685 79492513
Phospholipidosis 53.05 18.72 10 6180 226 79737972
Psoriasis 46.10 18.72 45 6145 89542 79648656
Anxiety 43.68 18.72 73 6117 248439 79489759
Stress cardiomyopathy 43.67 18.72 20 6170 11146 79727052
Subarachnoid haemorrhage 38.82 18.72 24 6166 24441 79713757
Deep vein thrombosis 38.21 18.72 47 6143 120872 79617326
Cholelithiasis 38.00 18.72 32 6158 52632 79685566
Product dose omission issue 34.84 18.72 66 6124 247471 79490727
Pain 31.02 18.72 122 6068 703680 79034518
Device dislocation 30.26 18.72 21 6169 25949 79712249
Dermatitis atopic 30.13 18.72 15 6175 10041 79728157
Spinal cord infarction 27.88 18.72 7 6183 616 79737582
Encephalomalacia 27.46 18.72 8 6182 1233 79736965
Cardio-respiratory arrest 26.25 18.72 37 6153 108473 79629725
Respiratory arrest 26.08 18.72 27 6163 57523 79680675
Toxicity to various agents 25.33 18.72 81 6109 421459 79316739
Anhedonia 24.61 18.72 15 6175 14883 79723315
Colitis ischaemic 24.19 18.72 15 6175 15344 79722854
Renal vein thrombosis 23.50 18.72 6 6184 565 79737633
Biliary dyskinesia 21.81 18.72 8 6182 2537 79735661
Device breakage 20.91 18.72 12 6178 10663 79727535
Subacute cutaneous lupus erythematosus 19.20 18.72 8 6182 3553 79734645
Pseudomembranous colitis 19.07 18.72 9 6181 5365 79732833
Scleroderma 18.85 18.72 9 6181 5501 79732697

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A08AA01 ALIMENTARY TRACT AND METABOLISM
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Centrally acting antiobesity products
ATC A08AA51 ALIMENTARY TRACT AND METABOLISM
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Centrally acting antiobesity products
FDA PE N0000175372 Appetite Suppression
FDA EPC N0000175423 Sympathomimetic Amine Anorectic
MeSH PA D018663 Adrenergic Agents
MeSH PA D019440 Anti-Obesity Agents
MeSH PA D001067 Appetite Depressants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013566 Sympathomimetics
CHEBI has role CHEBI:35337 analeptic
CHEBI has role CHEBI:35470 central nervous system agents
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:37962 adrenergic agents
CHEBI has role CHEBI:48560 dopaminergic agents
FDA PE N0000175651 Increased Sympathetic Activity

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Low blood pressure indication 45007003
Obesity indication 414916001 DOID:9970
Prevention of Hypotension During Spinal Anesthesia indication
Hypotension Secondary to Spinal Anesthesia indication
Heart valve disorder contraindication 368009 DOID:4079
Alcoholism contraindication 7200002
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Mild pre-eclampsia contraindication 41114007
Conduction disorder of the heart contraindication 44808001
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Pulmonary hypertension contraindication 70995007 DOID:6432
Secondary glaucoma contraindication 95717004
Angina pectoris contraindication 194828000
Edema contraindication 267038008
Syncope contraindication 271594007
Arteriosclerosis obliterans contraindication 361133006 DOID:5160
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.92 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 11.25MG BASE;69MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 11.25MG BASE;69MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 15MG BASE;92MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 15MG BASE;92MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 3.75MG BASE;23MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 3.75MG BASE;23MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 7.5MG BASE;46MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8895057 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 7.5MG BASE;46MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 9011906 June 9, 2028 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
EQ 11.25MG BASE;69MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY
EQ 15MG BASE;92MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY
EQ 3.75MG BASE;23MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY
EQ 7.5MG BASE;46MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8580299 June 14, 2029 FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 11.25MG BASE;69MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL June 24, 2025 NEW PATIENT POPULATION
EQ 15MG BASE;92MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL June 24, 2025 NEW PATIENT POPULATION
EQ 3.75MG BASE;23MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL June 24, 2025 NEW PATIENT POPULATION
EQ 7.5MG BASE;46MG QSYMIA VIVUS N022580 July 17, 2012 RX CAPSULE, EXTENDED RELEASE ORAL June 24, 2025 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR WOMBAT-PK CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 5.80 WOMBAT-PK

External reference:

IDSource
4019891 VUID
N0000147976 NUI
D05458 KEGG_DRUG
1197-21-3 SECONDARY_CAS_RN
4018166 VANDF
4018167 VANDF
4019891 VANDF
C0031447 UMLSCUI
CHEBI:8080 CHEBI
CHEMBL1574 ChEMBL_ID
DB00191 DRUGBANK_ID
CHEMBL1200912 ChEMBL_ID
D010645 MESH_DESCRIPTOR_UI
4771 PUBCHEM_CID
1064 INN_ID
7269 IUPHAR_LIGAND_ID
C045TQL4WP UNII
221138 RXNORM
1294 MMSL
41147 MMSL
5278 MMSL
5279 MMSL
d00806 MMSL
001864 NDDF
001865 NDDF
001866 NDDF
373343009 SNOMEDCT_US
426428004 SNOMEDCT_US
53480001 SNOMEDCT_US
6394006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
phentermine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0644 CAPSULE 15 mg ORAL ANDA 29 sections
phentermine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0647 CAPSULE 30 mg ORAL ANDA 29 sections
phentermine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-5000 CAPSULE 30 mg ORAL ANDA 29 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-0597 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-0597 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1308 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1308 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1310 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1310 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine ResinER HUMAN PRESCRIPTION DRUG LABEL 1 0527-1366 CAPSULE, EXTENDED RELEASE 30 mg ORAL ANDA 26 sections
Phentermine ResinER HUMAN PRESCRIPTION DRUG LABEL 1 0527-1398 CAPSULE, EXTENDED RELEASE 15 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1438 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1438 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1445 TABLET 37.50 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1445 TABLET 37.50 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1742 CAPSULE 15 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1742 CAPSULE 15 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1743 CAPSULE 37.50 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1743 CAPSULE 37.50 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-098 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-099 CAPSULE 15 mg ORAL ANDA 9 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-116 TABLET 37.50 mg ORAL ANDA 9 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-552 TABLET 30 mg ORAL ANDA 31 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-592 CAPSULE 37.50 mg ORAL ANDA 9 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-593 CAPSULE 30 mg ORAL ANDA 19 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-602 TABLET 37.50 mg ORAL ANDA 19 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-620 CAPSULE 30 mg ORAL ANDA 9 sections
LOMAIRA HUMAN PRESCRIPTION DRUG LABEL 1 10702-001 TABLET 8 mg ORAL ANDA 17 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-025 TABLET 37.50 mg ORAL ANDA 25 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-026 CAPSULE 15 mg ORAL ANDA 29 sections